Mangoceuticals (NASDAQ:MGRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Mangoceuticals (NASDAQ:MGRX) to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Mangoceuticals Trading Up 4.3%

Shares of NASDAQ:MGRX opened at $0.54 on Friday. The firm has a market cap of $9.32 million, a price-to-earnings ratio of -0.36 and a beta of 2.28. Mangoceuticals has a 1 year low of $0.16 and a 1 year high of $2.75. The business has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.42.

Mangoceuticals (NASDAQ:MGRX) last issued its earnings results on Tuesday, May 19th. The company reported ($0.22) EPS for the quarter. Mangoceuticals had a negative net margin of 4,639.13% and a negative return on equity of 112.00%. The firm had revenue of $0.07 million during the quarter.

Hedge Funds Weigh In On Mangoceuticals

A number of institutional investors have recently modified their holdings of MGRX. Geode Capital Management LLC lifted its stake in shares of Mangoceuticals by 35.4% in the second quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock worth $40,000 after buying an additional 6,928 shares during the last quarter. Virtu Financial LLC bought a new position in Mangoceuticals in the 4th quarter worth $25,000. Boothbay Fund Management LLC bought a new position in Mangoceuticals in the 4th quarter worth $28,000. Jane Street Group LLC acquired a new position in Mangoceuticals during the 4th quarter worth $35,000. Finally, Ikarian Capital LLC acquired a new position in Mangoceuticals during the 4th quarter worth $102,000. Institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.